Research Paper Volume 13, Issue 6 pp 8408—8420
Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy
Figure 2. PFS of patients (A) with CR+PR vs SD after dCRT, (B) with vs without fistula, and (C) with vs without any adverse event; OS of patients with (D) CR+PR vs SD after dCRT, (E) with vs without fistula, and (F) with vs without proteinuria.